vTv Therapeutics
VTVT
27 hedge funds and large institutions have $51.3M invested in vTv Therapeutics in 2025 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 3 reducing their positions, and 3 closing their positions.
167% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 3
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
123% more capital invested
Capital invested by funds: $23.1M → $51.3M (+$28.3M)
17% more funds holding
Funds holding: 23 → 27 (+4)
5.17% less ownership
Funds ownership: 37.76% → 32.6% (-5.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.11M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.01M |
| 3 |
6CM
683 Capital Management
New York
|
+$509K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$359K |
| 5 |
Pathstone Holdings
Englewood,
New Jersey
|
+$169K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$2.11M |
| 2 |
Millennium Management
New York
|
-$301K |
| 3 |
CCM
Connective Capital Management
Palo Alto,
California
|
-$227K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$36.2K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$13.9K |
VTVT Hedge Fund Activity: Q4 2025 in Review
27 of the 8,225 institutional investors tracked by Wall St. Rank reported a position in vTv Therapeutics (VTVT) for Q4 2025, worth a combined $51.3M — up 123% from $23.1M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new VTVT positions and 3 closed out — a net gain of 4 holders — while 8 added to existing stakes and 3 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $2.11M. The largest seller was Samsara BioCapital, cutting an estimated $2.11M.
- 27 institutional investors held vTv Therapeutics (VTVT) as of Q4 2025, up from 23 in Q3 2025.
- Funds reported $51.3M of vTv Therapeutics stock for Q4 2025, up 123% quarter-over-quarter.
- 7 funds opened new vTv Therapeutics positions in Q4 2025 and 3 closed out, a net change of +4 holders.
- The largest vTv Therapeutics buyer in Q4 2025 was Fidelity Investments, an estimated $2.11M added.
- The largest vTv Therapeutics seller in Q4 2025 was Samsara BioCapital, an estimated $2.11M sold.
Based on aggregated 13F filings for Q4 2025.